Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Please Do Squeeze the Tumor Cell

This article was originally published in Start Up

Executive Summary

A team at UCLA used nanomechanics to show that tumor cells are significantly more elastic than normal cells, suggesting that stiffness can accurately distinguish them from normal cells. The technique could be readily adopted in pathology labs to improve the accuracy of traditional cytology analysis using standard sample preparation and processing. Moreover, there may be an immediate opportunity to use it to diagnose mesothelioma, which is not now possible using visual analysis.

You may also be interested in...



J&J Snaps Up Rare Cell Capture And Analysis Technology From Mass General

Mass General has signed a $30 million deal with two units of J&J to develop a new system for capturing and analyzing circulating tumor cells (CTCs). The collaboration aims to develop a standardized diagnostic platform for biomarker analysis of DNA, RNA, or protein from tumor cells collected noninvasively. J&J will take the indications for its current CTC system, CellSearch, and migrate them to the new platform.

Overcoming Skepticism About Cancer Diagnostics

In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.

US FDA Oncology, Device Centers Developing Public Diagnostic Standards

Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel